Like It Or Not, FDA Is At The Center Of Drug Pricing Debate
This article was originally published in The Pink Sheet Daily
Executive Summary
House committees create demanding schedule for CDER's Woodcock, requiring her at two hearings 90 minutes apart.
You may also be interested in...
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
Agency plans to issue 102 new and revised draft guidances this year, including those on use of multiple endpoints in clinical trials, 180-day exclusivity, and ANDA refuse-to-receive standards.
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.